For example, the REPLACE study (A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Study to Investigate the Use of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1‐84]) for the Treatment of Adults With Hypoparathyroidism)(11, 39) reported a high number of mild adverse events, which might have increased the overall rate of side effects of PTH1−84 compared to PTH1−34. The gene discussed is PTH; the disease is hypoparathyroidism.